Marvel Biosciences Corp (MRVL) - Net Assets
Based on the latest financial reports, Marvel Biosciences Corp (MRVL) has net assets worth CA$-3.65 Million CAD as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$683.06K) and total liabilities (CA$4.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-3.65 Million |
| % of Total Assets | -534.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | -270.07% |
| 10-Year Change | N/A |
| Growth Volatility | 1196.35 |
Marvel Biosciences Corp - Net Assets Trend (2020–2025)
This chart illustrates how Marvel Biosciences Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Marvel Biosciences Corp (2020–2025)
The table below shows the annual net assets of Marvel Biosciences Corp from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-07-31 | CA$-4.01 Million | -41.77% |
| 2024-07-31 | CA$-2.83 Million | -64.28% |
| 2023-07-31 | CA$-1.72 Million | -979.68% |
| 2022-07-31 | CA$195.54K | -91.70% |
| 2021-07-31 | CA$2.36 Million | +1882.82% |
| 2020-07-31 | CA$118.80K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Marvel Biosciences Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1174642100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$8.90 Million | % |
| Total Equity | CA$-4.01 Million | 100.00% |
Marvel Biosciences Corp Competitors by Market Cap
The table below lists competitors of Marvel Biosciences Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wah Fu Education Group Ltd
NASDAQ:WAFU
|
$7.15 Million |
|
Innovotech Inc
V:IOT
|
$7.15 Million |
|
Pacific Nickel Mines Ltd
AU:PNM
|
$7.15 Million |
|
International Graphite Ltd
AU:IG6
|
$7.15 Million |
|
LOBO EV TECHNOLOGIES LTD. Ordinary shares
NASDAQ:LOBO
|
$7.13 Million |
|
Slam Exploration Ltd.
V:SXL
|
$7.13 Million |
|
Capri Nusa Satu Properti Tbk PT
JK:CPRI
|
$7.13 Million |
|
MILA RESOUR. PLC LS-01
F:HN0
|
$7.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Marvel Biosciences Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,825,804 to -4,006,237, a change of -1,180,433.
- Net loss of 2,211,468 reduced equity.
- New share issuances of 1,018,750 increased equity.
- Other factors increased equity by 12,285.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-2.21 Million | -55.2% |
| Share Issuances | CA$1.02 Million | +25.43% |
| Other Changes | CA$12.29K | +0.31% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Marvel Biosciences Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-07-31 | CA$0.00 | CA$0.17 | x |
| 2021-07-31 | CA$0.07 | CA$0.17 | x |
| 2022-07-31 | CA$0.01 | CA$0.17 | x |
| 2023-07-31 | CA$-0.04 | CA$0.17 | x |
| 2024-07-31 | CA$-0.06 | CA$0.17 | x |
| 2025-07-31 | CA$-0.08 | CA$0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Marvel Biosciences Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-373.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -804.40% | 0.00% | 0.00x | 2.49x | CA$-967.54K |
| 2021 | -129.02% | 0.00% | 0.00x | 1.05x | CA$-3.27 Million |
| 2022 | -1306.22% | 0.00% | 0.00x | 4.67x | CA$-2.57 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-2.12 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.37 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.81 Million |
Industry Comparison
This section compares Marvel Biosciences Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,953,624
- Average return on equity (ROE) among peers: -189.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Marvel Biosciences Corp (MRVL) | CA$-3.65 Million | -804.40% | N/A | $7.13 Million |
| Appili Therapeutics Inc (APLI) | $-10.92 Million | 0.00% | 0.00x | $1.39 Million |
| Aptose Biosciences Inc (APS) | $37.74 Million | -110.82% | 0.35x | $4.38 Million |
| Arch Biopartners Inc (ARCH) | $-174.98K | 0.00% | 0.00x | $22.08 Million |
| Biomind Labs Inc (BMND) | $2.19 Million | -197.55% | 0.15x | $6.98 Million |
| Devonian Health Group Inc (GSD) | $9.14 Million | -65.80% | 0.73x | $20.03 Million |
| Helix BioPharma Corp. (HBP) | $-90.00K | 0.00% | 0.00x | $109.95 Million |
| Hemostemix Inc (HEM) | $487.80K | -1268.49% | 2.41x | $9.54 Million |
| Universal Ibogaine Inc (IBO) | $94.89K | -124.68% | 0.23x | $1.13 Million |
| Innovotech Inc (IOT) | $644.98K | 16.48% | 0.28x | $7.15 Million |
| Kane Biotech Inc (KNE) | $426.65K | -141.23% | 0.23x | $3.63 Million |
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hal… Read more